[go: up one dir, main page]

WO2008123395A1 - ヒストン脱アセチル化酵素阻害作用を有する化合物を有効成分として含有する眼圧下降剤 - Google Patents

ヒストン脱アセチル化酵素阻害作用を有する化合物を有効成分として含有する眼圧下降剤 Download PDF

Info

Publication number
WO2008123395A1
WO2008123395A1 PCT/JP2008/056014 JP2008056014W WO2008123395A1 WO 2008123395 A1 WO2008123395 A1 WO 2008123395A1 JP 2008056014 W JP2008056014 W JP 2008056014W WO 2008123395 A1 WO2008123395 A1 WO 2008123395A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound capable
histone deacetylase
active ingredient
ocular hypotensive
hypotensive agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/056014
Other languages
English (en)
French (fr)
Inventor
Shinji Yoneda
Koushi Fujisawa
Katsuhiko Watanabe
Junko Fujikawa
Atsushi Shimazaki
Tomoko Kirihara
Hisashi Tajima
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Santen Pharmaceutical Co Ltd
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Priority to US12/450,388 priority Critical patent/US20100056522A1/en
Priority to CA002680838A priority patent/CA2680838A1/en
Priority to EP08739138A priority patent/EP2135620A4/en
Publication of WO2008123395A1 publication Critical patent/WO2008123395A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/333—Radicals substituted by oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

　本発明はＨＤＡＣ阻害作用を有する化合物の新たな薬理作用を見出すことを目的とする。本発明のヒストン脱アセチル化酵素阻害作用を有する化合物は、線維柱帯細胞に対して優れた細胞形態変化作用及び／又は眼圧下降作用を有するので、房水循環及び／又は眼圧が関与するとされる疾患の予防及び/又は治療剤、特に緑内障、高眼圧症の予防及び/又は治療剤として有用である。
PCT/JP2008/056014 2007-03-28 2008-03-28 ヒストン脱アセチル化酵素阻害作用を有する化合物を有効成分として含有する眼圧下降剤 Ceased WO2008123395A1 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US12/450,388 US20100056522A1 (en) 2007-03-28 2008-03-28 Intraocular pressure-lowering agent comprising compound having histone deacetylase inhibitor effect as active ingredient
CA002680838A CA2680838A1 (en) 2007-03-28 2008-03-28 Intraocular pressure-lowering agent comprising compound having histone deacetylase inhibitory effect as active ingredient
EP08739138A EP2135620A4 (en) 2007-03-28 2008-03-28 AGAINST OKULAR HYPOTONIA CONNECTED TO HISTONE DEACETYLASE INHIBITION AS AN ACTIVE SUBSTANCE

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-084356 2007-03-28
JP2007084356 2007-03-28

Publications (1)

Publication Number Publication Date
WO2008123395A1 true WO2008123395A1 (ja) 2008-10-16

Family

ID=39830880

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/056014 Ceased WO2008123395A1 (ja) 2007-03-28 2008-03-28 ヒストン脱アセチル化酵素阻害作用を有する化合物を有効成分として含有する眼圧下降剤

Country Status (7)

Country Link
US (1) US20100056522A1 (ja)
EP (1) EP2135620A4 (ja)
JP (1) JP2008266322A (ja)
KR (1) KR20090125209A (ja)
CN (1) CN101646460A (ja)
CA (1) CA2680838A1 (ja)
WO (1) WO2008123395A1 (ja)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009142321A1 (ja) * 2008-05-23 2009-11-26 参天製薬株式会社 ウレア構造を有する新規チオフェンジアミン誘導体
CN102459159A (zh) * 2009-06-08 2012-05-16 吉利德科学股份有限公司 烷酰基氨基苯甲酰胺苯胺hdac抑制剂化合物
JP2019531296A (ja) * 2016-09-29 2019-10-31 彦臣生技藥品股▲ふん▼有限公司ＮａｔｕｒｅＷｉｓｅ Ｂｉｏｔｅｃｈ＆ Ｍｅｄｉｃａｌｓ Ｃｏｒｐｏｒａｔｉｏｎ 眼疾患の処置方法

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2735593C (en) 2008-09-03 2017-08-15 Repligen Corporation Compositions including 6-aminohexanoic acid derivatives as hdac inhibitors
US8912184B1 (en) 2010-03-01 2014-12-16 Alzheimer's Institute Of America, Inc. Therapeutic and diagnostic methods
US10059723B2 (en) 2011-02-28 2018-08-28 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
EP2680694B1 (en) 2011-02-28 2019-01-02 BioMarin Pharmaceutical Inc. Histone deacetylase inhibitors
US8957066B2 (en) 2011-02-28 2015-02-17 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
MX370142B (es) 2013-03-15 2019-12-03 Biomarin Pharm Inc Inhibidores de hdac.
USRE49240E1 (en) * 2013-11-05 2022-10-11 The General Hospital Corporation Inhibitors of histone deacetylase
KR102234258B1 (ko) 2019-01-28 2021-03-31 경북대학교 산학협력단 안압이 상승된 동물 모델, 그의 제조방법 및 그를 이용한 녹내장 치료제의 스크리닝 방법

Citations (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005723A1 (fr) 1988-11-24 1990-05-31 Yoshitomi Pharmaceutical Industries, Ltd. Composes de trans-4-amino(alkyl)-1-pyridylcarbamoylcyclohexane et leur utilisation en medecine
WO1997030701A2 (en) 1996-02-21 1997-08-28 Wisconsin Alumni Research Foundation Pharmaceutical compositions for the treatment of glaucoma
JPH10152462A (ja) 1996-09-30 1998-06-09 Mitsui Chem Inc 分化誘導剤
JPH11269146A (ja) 1998-03-24 1999-10-05 Mitsui Chem Inc 分化誘導剤
JPH11269140A (ja) 1998-03-23 1999-10-05 Mitsui Chem Inc 分化誘導剤
JPH11302173A (ja) 1998-04-16 1999-11-02 Mitsui Chem Inc ヒストン脱アセチル化酵素阻害剤
JPH11335373A (ja) 1998-05-25 1999-12-07 Taisho Pharmaceut Co Ltd アリールメチレンピペリジノピリミジン誘導体
JPH11335375A (ja) 1998-05-20 1999-12-07 Mitsui Chem Inc ヒストン脱アセチル化酵素阻害作用を有するベンズアミド誘導体
WO2000009162A1 (en) 1998-08-17 2000-02-24 Senju Pharmaceutical Co., Ltd. Preventives/remedies for glaucoma
JP2001064177A (ja) 1999-08-16 2001-03-13 Schering Ag ベンズアミド誘導体を有効成分とする製剤
JP2001081031A (ja) 1999-08-30 2001-03-27 Schering Ag 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤
JP2001316283A (ja) 2000-02-28 2001-11-13 Yasushi Kaneda 遺伝子発現増強剤
WO2002022577A2 (en) 2000-09-01 2002-03-21 Novartis Ag Hydroxamate derivatives useful as deacetylase inhibitors
WO2002030879A2 (en) 2000-09-29 2002-04-18 Prolifix Limited Carbamic acid compounds comprising a sulfonamide linkage as hdac inhibitors
JP2002332267A (ja) 1996-09-30 2002-11-22 Schering Ag 分化誘導剤
JP2003226680A (ja) 1991-10-04 2003-08-12 Sloan-Kettering Inst For Cancer Research 新規の有効な末端分化誘発剤およびその使用方法
WO2003087057A1 (en) 2002-04-05 2003-10-23 Astrazeneca Ab Benzamide derivatives useful as histone deacetylase inhibitors
WO2003092686A1 (en) 2002-04-27 2003-11-13 Astrazeneca Ab Inhibitors of histone deacetylase
WO2004035525A1 (en) 2002-10-17 2004-04-29 Methylgene Inc. Inhibitors of histone deacetylase
WO2004052838A1 (en) 2002-12-10 2004-06-24 F. Hoffmann-La Roche Ag Arylene-carboxylic acid (2-amino-phenyl)-amide derivatives as pharmaceutical agents
WO2004069823A1 (en) 2003-02-04 2004-08-19 Methylgene, Inc. Inhibitors of histone deacetylase
WO2004069133A2 (en) 2003-02-07 2004-08-19 F. Hoffmann-La Roche Ag N-monoacylated o-phenylenediamines as anti -cancer agents
US20040162317A1 (en) 2003-02-06 2004-08-19 Georg Fertig Mono-acylated o-phenylendiamines derivatives
WO2004087693A1 (en) 2003-04-04 2004-10-14 F. Hoffmann-La Roche Ag Oxime derivatives and their use as pharmaceutically active agents
WO2004092115A2 (en) 2003-04-07 2004-10-28 Axys Pharmaceuticals Inc. Hydroxamates as therapeutic agents
WO2005019174A1 (en) 2003-08-20 2005-03-03 Axys Pharmaceuticals, Inc. Acetylene derivatives as inhibitors of histone deacetylase
JP2005272419A (ja) 2004-03-26 2005-10-06 Nippon Kayaku Co Ltd ヒストン脱アセチル化酵素阻害剤
JP2006517532A (ja) 2003-01-17 2006-07-27 トポターゲット ユーケー リミテッド Ｈｄａｃ阻害剤としてのエステル又はケトン結合を含むカルバミン酸化合物
JP2007001885A (ja) 2005-06-21 2007-01-11 Univ Kansai カルボキサミド誘導体

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1711086A (zh) * 2002-11-12 2005-12-21 爱尔康公司 用于治疗眼的退化性疾病的组蛋白脱乙酰酶抑制剂
JP2007191398A (ja) * 2006-01-17 2007-08-02 Saisentan Igaku Kenkyusho:Kk 眼疾患治療剤
CN101646651A (zh) * 2007-03-28 2010-02-10 参天制药株式会社 具有脲结构的新型吡啶羧酸（2-氨基苯基）酰胺衍生物

Patent Citations (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005723A1 (fr) 1988-11-24 1990-05-31 Yoshitomi Pharmaceutical Industries, Ltd. Composes de trans-4-amino(alkyl)-1-pyridylcarbamoylcyclohexane et leur utilisation en medecine
JP2003226680A (ja) 1991-10-04 2003-08-12 Sloan-Kettering Inst For Cancer Research 新規の有効な末端分化誘発剤およびその使用方法
WO1997030701A2 (en) 1996-02-21 1997-08-28 Wisconsin Alumni Research Foundation Pharmaceutical compositions for the treatment of glaucoma
JP2002332267A (ja) 1996-09-30 2002-11-22 Schering Ag 分化誘導剤
JPH10152462A (ja) 1996-09-30 1998-06-09 Mitsui Chem Inc 分化誘導剤
JPH11269140A (ja) 1998-03-23 1999-10-05 Mitsui Chem Inc 分化誘導剤
JPH11269146A (ja) 1998-03-24 1999-10-05 Mitsui Chem Inc 分化誘導剤
JPH11302173A (ja) 1998-04-16 1999-11-02 Mitsui Chem Inc ヒストン脱アセチル化酵素阻害剤
JPH11335375A (ja) 1998-05-20 1999-12-07 Mitsui Chem Inc ヒストン脱アセチル化酵素阻害作用を有するベンズアミド誘導体
JPH11335373A (ja) 1998-05-25 1999-12-07 Taisho Pharmaceut Co Ltd アリールメチレンピペリジノピリミジン誘導体
WO2000009162A1 (en) 1998-08-17 2000-02-24 Senju Pharmaceutical Co., Ltd. Preventives/remedies for glaucoma
JP2001064177A (ja) 1999-08-16 2001-03-13 Schering Ag ベンズアミド誘導体を有効成分とする製剤
JP2001081031A (ja) 1999-08-30 2001-03-27 Schering Ag 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤
JP2001316283A (ja) 2000-02-28 2001-11-13 Yasushi Kaneda 遺伝子発現増強剤
WO2002022577A2 (en) 2000-09-01 2002-03-21 Novartis Ag Hydroxamate derivatives useful as deacetylase inhibitors
WO2002030879A2 (en) 2000-09-29 2002-04-18 Prolifix Limited Carbamic acid compounds comprising a sulfonamide linkage as hdac inhibitors
WO2003087057A1 (en) 2002-04-05 2003-10-23 Astrazeneca Ab Benzamide derivatives useful as histone deacetylase inhibitors
WO2003092686A1 (en) 2002-04-27 2003-11-13 Astrazeneca Ab Inhibitors of histone deacetylase
WO2004035525A1 (en) 2002-10-17 2004-04-29 Methylgene Inc. Inhibitors of histone deacetylase
WO2004052838A1 (en) 2002-12-10 2004-06-24 F. Hoffmann-La Roche Ag Arylene-carboxylic acid (2-amino-phenyl)-amide derivatives as pharmaceutical agents
JP2006509021A (ja) * 2002-12-10 2006-03-16 エフ．ホフマン−ラ　ロシュ　アーゲー 薬剤としてのアリーレンカルボン酸（２−アミノ−フェニル）−アミド誘導体
JP2006517532A (ja) 2003-01-17 2006-07-27 トポターゲット ユーケー リミテッド Ｈｄａｃ阻害剤としてのエステル又はケトン結合を含むカルバミン酸化合物
WO2004069823A1 (en) 2003-02-04 2004-08-19 Methylgene, Inc. Inhibitors of histone deacetylase
JP2006514998A (ja) 2003-02-04 2006-05-18 メシルジーン、インコーポレイテッド ヒストンデアセチラーゼの阻害剤
US20040162317A1 (en) 2003-02-06 2004-08-19 Georg Fertig Mono-acylated o-phenylendiamines derivatives
WO2004069133A2 (en) 2003-02-07 2004-08-19 F. Hoffmann-La Roche Ag N-monoacylated o-phenylenediamines as anti -cancer agents
WO2004087693A1 (en) 2003-04-04 2004-10-14 F. Hoffmann-La Roche Ag Oxime derivatives and their use as pharmaceutically active agents
WO2004092115A2 (en) 2003-04-07 2004-10-28 Axys Pharmaceuticals Inc. Hydroxamates as therapeutic agents
WO2005019174A1 (en) 2003-08-20 2005-03-03 Axys Pharmaceuticals, Inc. Acetylene derivatives as inhibitors of histone deacetylase
JP2005272419A (ja) 2004-03-26 2005-10-06 Nippon Kayaku Co Ltd ヒストン脱アセチル化酵素阻害剤
JP2007001885A (ja) 2005-06-21 2007-01-11 Univ Kansai カルボキサミド誘導体

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
CANCER RES., vol. 47, 1987, pages 3688 - 3691
COFFEY D.C. ET AL.: "The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans retinoic acid", CANCER RES., vol. 61, no. 9, 2001, pages 3591 - 3594, XP008117801 *
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 41, 2006, pages 697
EXP. CELL RES., vol. 177, 1988, pages 122 - 131
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, vol. 42, 2001, pages 137 - 144
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, vol. 43, 2002, pages 151 - 161
J. ANTIBIOTICS, vol. 43, 1990, pages 1524 - 1534
J. BIOL. CHEM., vol. 254, 1979, pages 1716 - 1723
J. BIOL. CHEM., vol. 265, 1990, pages 17174 - 17179
J. BIOL. CHEM., vol. 268, 1993, pages 22429 - 22435
JOURNAL OF MEDICINAL CHEMISTRY, vol. 45, 2002, pages 753
MONNERET C.: "Histone deacetylase inhibitors", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 40, 2005, pages 1 - 13, XP004708959 *
PROTEIN, NUCLEIC ACID AND ENZYME, vol. 51, no. 14, 2006
TAKAI N. ET AL.: "M344 is a novel synthesized histone deacetylase inhibitor that induces growth inhibition, cell cycle arrest, and apoptosis in human, endometrial cancer and ovarian cancer cells", GYNECOL. ONCOL., vol. 101, no. 1, 2006, pages 108 - 113, XP005300676 *
THE JOURNAL OF CLINICAL INVESTIGATION, vol. 103, 1999, pages 1141 - 1150

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009142321A1 (ja) * 2008-05-23 2009-11-26 参天製薬株式会社 ウレア構造を有する新規チオフェンジアミン誘導体
CN102459159A (zh) * 2009-06-08 2012-05-16 吉利德科学股份有限公司 烷酰基氨基苯甲酰胺苯胺hdac抑制剂化合物
JP2019531296A (ja) * 2016-09-29 2019-10-31 彦臣生技藥品股▲ふん▼有限公司ＮａｔｕｒｅＷｉｓｅ Ｂｉｏｔｅｃｈ＆ Ｍｅｄｉｃａｌｓ Ｃｏｒｐｏｒａｔｉｏｎ 眼疾患の処置方法
US11045435B2 (en) 2016-09-29 2021-06-29 Naturewise Biotech & Medicals Corporation Methods for treating ocular diseases
JP2021138710A (ja) * 2016-09-29 2021-09-16 彦臣生技藥品股▲ふん▼有限公司NatureWise Biotech & Medicals Corporation 眼疾患の処置方法
JP2023116748A (ja) * 2016-09-29 2023-08-22 彦臣生技藥品股▲ふん▼有限公司 眼疾患の処置方法

Also Published As

Publication number Publication date
CA2680838A1 (en) 2008-10-16
US20100056522A1 (en) 2010-03-04
EP2135620A1 (en) 2009-12-23
JP2008266322A (ja) 2008-11-06
KR20090125209A (ko) 2009-12-03
CN101646460A (zh) 2010-02-10
EP2135620A4 (en) 2010-12-29

Similar Documents

Publication Publication Date Title
WO2008123395A1 (ja) ヒストン脱アセチル化酵素阻害作用を有する化合物を有効成分として含有する眼圧下降剤
CA2661102C (en) Thiophene derivatives as s1p1/edg1 receptor agonists
WO2009074950A3 (en) Thiophene derivatives as agonists of s1p1/edg1
WO2006100635A3 (en) Novel thiophene derivatives as sphingosine-1-phosphate-1 receptor agonists
WO2005068421A8 (en) Prostaglandin nitrooxyderivatives
EP2966078A3 (en) Inhibitors of histone deacetylase
WO2006049835A3 (en) Indole and benzimidazole derivatives
WO2006066133A3 (en) Histone deacetylase inhibitors
WO2008120759A1 (ja) ウレア化合物およびその用途
MY154909A (en) Novel thiophene derivatives
WO2009054479A1 (ja) スピロ環化合物及びその医薬用途
WO2009072604A1 (ja) 抗nr10抗体、およびその利用
WO2007084728A3 (en) 2-imino-benzimidazoles
MY147949A (en) Hydrogenated benzo[c]thiophene derivatives as immunomodulators
WO2011018582A3 (fr) Microgranulés flottants
EP1864665A4 (en) IMMUNOSUPPRESSIVE AGENT AND ANTI-TUMOR AGENT COMPRISING A HETEROCYCLIC COMPOUND AS ACTIVE INGREDIENT
WO2011084991A3 (en) Fluorinated hdac inhibitors and uses thereof
WO2009051119A1 (ja) ピリミジルインドリン化合物
WO2011012816A3 (fr) Formulation pharmaceutique
WO2010144378A3 (en) Cycloalkylcarbamate benzamide aniline hdac inhibitor compounds
WO2009041663A1 (ja) 皮膚疾患の予防及び／または治療剤
WO2010102824A3 (en) Sodium salt of 5-cyclopropyl-2-{[2-(2,6- difluorophenyl)pyrimidin-5-yl]amino}benzoic acid as dhodh inhibitor
WO2009060952A1 (ja) 新規製剤
WO2009082526A3 (en) Ortho pyrrolidine, benzyl-substituted heterocycle ccr1 antagonists for autoimmune diseases & inflammation
WO2008120744A1 (ja) ５員環アミド化合物およびその用途

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880010302.X

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08739138

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2680838

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 12450388

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008739138

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20097022488

Country of ref document: KR

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: JP